Trypanothione reductase

• Verfasst von: Beig, Mathias [VerfasserIn]
• Verfasst von: Oellien, Frank [VerfasserIn]
• Verfasst von: Garoff, Linnéa [VerfasserIn]
• Verfasst von: Noack, Sandra [VerfasserIn]
• Verfasst von: Krauth-Siegel, Renate [VerfasserIn]
• Verfasst von: Selzer, P. M. [VerfasserIn]
• Titel: Trypanothione reductase
• Titelzusatz: a target protein for a combined in vitro and in silico screening approach
• Verf.angabe: Mathias Beig, Frank Oellien, Linnéa Garoff, Sandra Noack, R. Luise Krauth-Siegel, Paul M. Selzer
• E-Jahr: 2015
• Jahr: June 4, 2015
• Fussnoten: Gesehen am 05.08.2020
• Titel Quelle: Enthalten in: Public Library of SciencePLoS neglected tropical diseases
• Ort Quelle: Lawrence, Kan. : PLoS, 2007
• Jahr Quelle: 2015
• Band/Heft Quelle: 9(2015) Artikel-Nummer e0003773, 19 Seiten
• ISSN Quelle: 1935-2735
• DOI: doi:10.1371/journal.pntd.0003773
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Drug screening
• Sach-SW: Enzyme kinetics
• Sach-SW: High throughput screening
• Sach-SW: Library screening
• Sach-SW: Solubility
• Sach-SW: Trypanosoma
• Sach-SW: Trypanosoma brucei gambiense
• Sach-SW: Trypanosoma cruzi
• K10plus-PPN: 1726219496

Abstract

With the goal to identify novel trypanothione reductase (TR) inhibitors, we performed a combination of in vitro and in silico screening approaches. Starting from a highly diverse compound set of 2,816 compounds, 21 novel TR inhibiting compounds could be identified in the initial in vitro screening campaign against T. cruzi TR. All 21 in vitro hits were used in a subsequent similarity search-based in silico screening on a database containing 200,000 physically available compounds. The similarity search resulted in a data set containing 1,204 potential TR inhibitors, which was subjected to a second in vitro screening campaign leading to 61 additional active compounds. This corresponds to an approximately 10-fold enrichment compared to the initial pure in vitro screening. In total, 82 novel TR inhibitors with activities down to the nM range could be identified proving the validity of our combined in vitro/in silico approach. Moreover, the four most active compounds, showing IC50 values of <1 μM, were selected for determining the inhibitor constant. In first on parasites assays, three compounds inhibited the proliferation of bloodstream T. brucei cell line 449 with EC50 values down to 2 μM.